Li Zhiyong, Wang Zhiming, Gan Hexia, Shen Feng, Cheng Lisha, Zhang Xiuping
Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China.
Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen, Fujian, China.
Future Sci OA. 2025 Dec;11(1):2532327. doi: 10.1080/20565623.2025.2532327. Epub 2025 Jul 16.
Pancreatic cancer (PC) is often diagnosed at advanced stages, limiting surgical options. There is no standardized treatment for second-line or beyond therapies, necessitating alternative treatments. This study evaluates the efficacy and safety of anlotinib combined with chemotherapy in advanced PC patients receiving second-line or subsequent treatments.
A retrospective analysis of 68 advanced PC patients was conducted. Twenty-six patients treated with anlotinib and chemotherapy were compared to 42 controls who received chemotherapy only. Demographic data, efficacy, survival, and adverse reactions were analyzed.
In the anlotinib group, the therapeutic responses were as follows: Complete Response: 0, Partial Response: 2 (7.7%), Stable Disease: 13 (50.0%), and Progressive Disease: 11 (42.3%), the Objective Remission Rate was 7.7%, and the Disease Control Rate was 57.7%. The median Progression-Free Survival was 4.5 months. The Overall Survival was significantly longer in the anlotinib group compared to controls. Common adverse reactions included fatigue, bone marrow suppression, and hypertension, mostly grade 1-3. The potential toxicity and cumulative toxicity of long-term use is hand-foot syndrome, hypothyroidism and hypertension.
The data generated suggest that anlotinib combined with chemotherapy may be an effective and tolerable option for second-line and subsequent treatment of advanced PC.
胰腺癌（PC）常在晚期被诊断出来，这限制了手术选择。对于二线及以上治疗尚无标准化方案，因此需要替代治疗。本研究评估了安罗替尼联合化疗在接受二线或后续治疗的晚期PC患者中的疗效和安全性。
对68例晚期PC患者进行回顾性分析。将26例接受安罗替尼联合化疗的患者与42例仅接受化疗的对照组进行比较。分析人口统计学数据、疗效、生存率和不良反应。
在安罗替尼组中，治疗反应如下：完全缓解：0例，部分缓解：2例（7.7%），病情稳定：13例（50.0%），病情进展：11例（42.3%），客观缓解率为7.7%，疾病控制率为57.7%。无进展生存期的中位数为4.5个月。与对照组相比，安罗替尼组的总生存期明显更长。常见的不良反应包括疲劳、骨髓抑制和高血压，大多为1-3级。长期使用的潜在毒性和累积毒性为手足综合征、甲状腺功能减退和高血压。
所获得的数据表明，安罗替尼联合化疗可能是晚期PC二线及后续治疗的一种有效且可耐受的选择。
